First-in-human (FIH) phase I dose escalation study (part A) of the first oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3Kδ) roginolisib in patients with advanced cancer and dose confirmation in uveal melanoma (part B).

被引：0
|
作者：
Di Giacomo, Anna Maria
Santangelo, Federica
Amato, Giovanni
Simonetti, Elena
Graham, Jill
Lahn, Michael M. F.
Di Conza, Giusy
Hammett, Tracey
Zorrilla, Rebeca
Durini, Marco
Tan, Ziyang
Tadepally, Lakshmikanth
Brodin, Petter
Occhipinti, Mariaelena
Simonelli, Matteo
Carlo-Stella, Carmelo
Santoro, Armando
Spiliopoulou, Pavlina
Evans, T. R. Jeffry
Maio, Michele
机构：
[1] Univ Hosp Siena, Ctr Immuno Oncol, Siena, Italy
[2] Azienda Osped Univ Senese, UOC Immunoterapia Oncolog, Siena, Italy
[3] Univ Siena, Siena, Italy
[4] Beatson Canc Ctr, Glasgow, Lanark, Scotland
[5] iOnctura SA, Geneva, Switzerland
[6] Covance Clin & Peri Approval Serv LTD, Milan, Italy
[7] Karolinska Inst, Stockholm, Sweden
[8] Karolinska Inst, Dept Womens & Childrens Hlth, Sci Life Lab, Solna, Sweden
[9] Radiomics, Liege, Belgium
[10] Humanitas Univ, Dept Biomed Sci, Milan, Italy
[11] Humanitas Univ, Milan, Italy
[12] IRCCS Humanitas Res Hosp, Milan, Italy
[13] IRCCS Humanitas Res Hosp, Rozzano, Italy
[14] Princess Margaret Canc Ctr Canada, Toronto, ON, Canada
[15] Univ Glasgow, Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3110
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A phase I dose-escalation study of the safety and pharmacokinetics of a tablet formulation of voxtalisib, a phosphoinositide 3-kinase inhibitor, in patients with solid tumors
    Mehnert, Janice M.
    Edelman, Gerald
    Stein, Mark
    Camisa, Heather
    Lager, Joanne
    Dedieu, Jean-Francois
    Ghuysen, Anne-Frederique
    Sharma, Jyoti
    Liu, Li
    LoRusso, Patricia M.
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (01) : 36 - 44
  • [32] A phase I dose-escalation study of the safety and pharmacokinetics of a tablet formulation of voxtalisib, a phosphoinositide 3-kinase inhibitor, in patients with solid tumors
    Janice M. Mehnert
    Gerald Edelman
    Mark Stein
    Heather Camisa
    Joanne Lager
    Jean-François Dedieu
    Anne-Frédérique Ghuysen
    Jyoti Sharma
    Li Liu
    Patricia M. LoRusso
    Investigational New Drugs, 2018, 36 : 36 - 44
  • [33] First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan-Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors
    Sarker, Debashis
    Ang, Joo Ern
    Baird, Richard
    Kristeleit, Rebecca
    Shah, Krunal
    Moreno, Victor
    Clarke, Paul A.
    Raynaud, Florence I.
    Levy, Gallia
    Ware, Joseph A.
    Mazina, Kathryn
    Lin, Ray
    Wu, Jenny
    Fredrickson, Jill
    Spoerke, Jill M.
    Lackner, Mark R.
    Yan, Yibing
    Friedman, Lori S.
    Kaye, Stan B.
    Derynck, Mika K.
    Workman, Paul
    de Bono, Johann S.
    CLINICAL CANCER RESEARCH, 2015, 21 (01) : 77 - 86
  • [34] First-in-human phase Ia study of the PI3Kα inhibitor CYH33 in patients with solid tumors
    Wei, Xiao-Li
    Liu, Fu-Rong
    Liu, Ji-Hong
    Zhao, Hong-Yun
    Zhang, Yang
    Wang, Zhi-Qiang
    Qiu, Miao-Zhen
    Xu, Fei
    Yu, Qiu-Qiong
    Du, Yi-Wu
    Shi, Yan-Xia
    Wang, De-Sheng
    Wang, Feng-Hua
    Xu, Rui-Hua
    NATURE COMMUNICATIONS, 2022, 13 (01)
  • [35] A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours
    Schram, Alison M.
    Gandhi, Leena
    Mita, Monica M.
    Damstrup, Lars
    Campana, Frank
    Hidalgo, Manuel
    Grande, Enrique
    Hyman, David M.
    Heist, Rebecca S.
    BRITISH JOURNAL OF CANCER, 2018, 119 (12) : 1471 - 1476
  • [36] First-in-human phase Ia study of the PI3Kα inhibitor CYH33 in patients with solid tumors
    Xiao-Li Wei
    Fu-Rong Liu
    Ji-Hong Liu
    Hong-Yun Zhao
    Yang Zhang
    Zhi-Qiang Wang
    Miao-Zhen Qiu
    Fei Xu
    Qiu-Qiong Yu
    Yi-Wu Du
    Yan-Xia Shi
    De-Sheng Wang
    Feng-Hua Wang
    Rui-Hua Xu
    Nature Communications, 13
  • [37] A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours
    Alison M. Schram
    Leena Gandhi
    Monica M. Mita
    Lars Damstrup
    Frank Campana
    Manuel Hidalgo
    Enrique Grande
    David M. Hyman
    Rebecca S. Heist
    British Journal of Cancer, 2018, 119 : 1471 - 1476
  • [38] First-in-human phase I dose-escalation study of a MET/AXL/FGFR inhibitor, S 49076, in patients with advanced solid tumors
    Azaro, A.
    Rodon, J.
    Herranz, M.
    Nuciforo, P.
    Prudkin, L.
    Lopez-Busto, N.
    Balandraud, S.
    Cattan, V.
    Jacquet-Bescond, A.
    Marfai, L.
    Pauly, J.
    Postel-Vinay, S.
    Hollebecque, A.
    Soria, J. C.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S54 - S54
  • [39] A first-in-human phase I dose escalation study of BET inhibitor GSK2820151 in patients with advanced or recurrent solid tumors cancers
    Gadgeel, Shirish
    Keedy, Vicki
    Taylor, Simon
    Amin, Khalid
    Homer, Thierry
    Wu, Yuehui
    Prinjha, Rab
    Dhar, Arindam
    Kremer, Brandon
    CANCER RESEARCH, 2017, 77
  • [40] First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic Cancer
    Blagden, Sarah
    Olmin, Aurelius
    Josephs, Debra
    Stavraka, Chara
    Zivi, Andrea
    Pinato, David J.
    Anthoney, Alan
    Decordova, Shaun
    Swales, Karen
    Riisnaes, Ruth
    Pope, Lorna
    Noguchi, Kohei
    Shiokawa, Rie
    Inatani, Michiyasu
    Prince, Jenny
    Jones, Keith
    Twelves, Chris
    Spicer, James
    Banerji, Udai
    CLINICAL CANCER RESEARCH, 2014, 20 (23) : 5908 - 5917
12345